$19.09

-0.31 (-1.60%)

7/18/2008 4:00 PM

Quidel Corp (QDEL)

CAPS Rating:

The Company is engaged in the development, manufacturing and marketing of rapid diagnostic solutions at the professional point-of-care in infectious diseases and reproductive health.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating QDEL

Add Stock to Watchlist

What the Community Thinks

Total Players

123 Outperforms

4 Underperforms

All-Stars

35 Outperforms

2 Underperforms

Wall Street

6 Outperforms

1 Underperforms

Players bullish on QDEL are also bullish on:

Players bearish on QDEL are also bearish on:

Ticker Tags

Diagnostic Substances (53), Micro Cap (4824), Small Cap (1922)
Suggest a tag

Quidel Corp At A Glance

Current Price:	$19.09
Last Trade Time:	7/18/2008 4:00 PM
Open:	$19.42
Previous Close:	$19.40
Daily Range:	$18.93 - $19.51
52-Week Range:	$12.95 - $21.07
Volume:	223,221
Market Cap:	$627.40M
P/E Ratio:	35.27
Compare Our Special Broker Offers!

Stock Trends

QDEL VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for QDEL

Sector Snap: Medical Diagnostics
3/4/2008 12:02:00 PM - AP
Quidel 4Q Profit Tumbles, Shares Fall
2/21/2008 6:04:00 PM - AP

More Headlines...

Top Bull Pitch

Recs

1 Quidel Corp (QDEL)

Avatar darksarab (23.62) Submitted: 1/27/08 11:39 PM

Healthcare needs have been trending towards more in office tests and treatments for quite a while. This is one of those rare cases where the demand for the comapany's products will be able to drive it no matter what the market is doing. This one is well positioned in a growing market with no end in ...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Players

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 16 : 1 2 3 4 Next »

Recs 0 (QDEL) johnwoo88 (< 20) Submitted: 7/17/08 11:38 AM : Start Price: $18.85 QDEL Score: -2.24 900000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000 Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (QDEL) caustexx (84.58) Submitted: 7/07/08 6:25 PM : Start Price: $16.35 QDEL Score: 15.91 courtesy of stockboxfinancial: The Short Story: Quidel Corp. is a company that develops and manufactures rapid point of care testing devices to diagnose such things as influenza. Through generating large amounts of free cash flow the company has been able to substantially buy back stock while continuing to develop new products. In Depth Analysis: Quidel is one of those companies that I am just dying to own. They have excellent management, low capital expenditures, a large (and growing) net cash position, have competitive advantages, and are buying back stock. For those of you who don’t know Quidel they manufacture point-of-care diagnostic tests. Doctors use point-of-care tests in order to diagnose a specific disease. If this sounds similar to the products made by companies like China Medical Technologies (CMED), well it is. There is a big difference however between Quidel and more traditional diagnostic applications: point-of-care tests do not require processing from a lab or laboratory equipment. This leads us right into the heart of Quidel’s business model. The company tries to engineer every product to live up to its “Quidel Value Build” criterion. This criterion revolves around “clinical validation” and “economic validation.” According to management clinical validation is “the enabling of rapid patient management decisions leading to improved treatment and outcomes.” Economic valuation is “the reduction of overall costs associated with patient testing emphasis upon critical reimbursement and payer performance criteria.” Quidel looks to produce products that perform better in clinical trials than alternatives, but are also cheaper as well. The company has been successful in this endeavor evinced by strong clinical performance and revenue growth of 20 percent over the last year. Since these tests are disposable, the company has a re-occurring revenue stream. In the past, Quidel sold products mainly in America, some parts of Europe and Japan. This is all about to change as the company recently created a partnership with bioMerieux. bioMerieux has operations in over 160 countries and this should allow Quidel to penetrate many international markets. In addition to distribution, Quidel and bioMeriuex will co-develop many products in such areas as upper respiratory and sexually transmitted diseases. This firm generates the majority of its revenue from influenza tests. In 2007 influenza tests accounted for 64 percent of revenue but Influenza is a fickle disease. Last year the season started seven weeks late in America and was one-third the normal strength in Japan. Since Quidel’s upper respiratory test for the flu has a shelf life of two years a weak influenza season could wreck havoc on the firm’s operations. Management and CEO Caren Mason are extremely competent and passionate about the business. During the latest conference call Ms. Mason could hardly contain her excitement about the company’s new products R&D efforts. Also, in earnings press releases the company discloses the amount of stock compensation expense something that is extremely rare in corporate America today. After backing out the companies large cash hoard Quidel is trading at 18.9 times free cash flow. Even though this is not a pricey valuation for a company of this quality, there is not a significant enough margin of safety to justify investment. However, management believed the company was undervalued earlier this year as they bought back a stock $6.6 million in stock (about 5 times stock compensation expense) at an average price of $14.33 a share. For now I find Quidel too pricey for my tastes, but I will be waiting for an opportunity in the future especially during this volatile market. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (QDEL) maryandtommy (69.16) Submitted: 3/13/08 11:07 PM : Start Price: $14.86 QDEL Score: 33.53 The wave of the future in health care diagnostics with rapid point of care results, no wait for transit to a lab and culture growth, eliminating the need for f/u visits/calls for results/answers. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (QDEL) thearistocrats (67.57) Submitted: 2/24/08 9:03 PM : Start Price: $16.58 QDEL Score: -22.14 Cramer pick that just lost it's mo Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (QDEL) DonewithCorpAmer (< 20) Submitted: 2/16/08 4:21 PM : Start Price: $17.60 QDEL Score: 16.25 Flu season is turning out to be more intense. Qdel makes the flu tests. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 16 : 1 2 3 4 Next »

Wall Street

Results 1 - 7 of 7

picks per page. CHANGE

Top Pick	Player Name	Player Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackJimCramer	82.55	02/15/08 02/15/08		3W	$15.97	+19.54%	-6.73%	+26.26
	TrackPacificGrow	85.90	01/16/08 01/16/08		NS	$17.00	+12.29%	-7.97%	+20.26
	TrackLazardCapit	78.47	11/19/07 11/19/07		NS	$17.84	+7.01%	-12.23%	+19.23
	TrackStifel	93.92	11/16/07 11/16/07		NS	$18.05	+5.76%	-13.00%	+18.76
	TrackGaryBSmith	57.58	06/29/07 06/29/07		3W	$17.56	+8.71%	-16.21%	+24.92
	TrackCarisandCo	79.10	02/16/07 02/16/07		NS	$11.83	+61.37%	-13.33%	+74.70
	TrackMatrix	89.88	08/29/06 08/29/06		NS	$11.00	+73.55%	-3.40%	-76.95

Results 1 - 7 of 7

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.